A New Hope for Autoimmune Diseases
A groundbreaking technique has emerged that could revolutionize the treatment of autoimmune conditions by targeting and eliminating the rogue cells responsible for these diseases. This innovative approach may offer a one-time treatment option for millions of people suffering from debilitating autoimmune disorders.
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage. In the UK alone, around four million people live with such conditions. Examples include rheumatoid arthritis, which affects the joints; type 1 diabetes, which targets insulin-producing cells in the pancreas; and multiple sclerosis, which damages the nerves, causing numbness and movement difficulties.
The new treatment involves using the body’s natural defenders—known as natural killer (NK) cells—to destroy the faulty white blood cells that produce harmful antibodies. Early trials have shown that this method not only improves symptoms but also "resets" the immune system, potentially offering long-term relief.
Current treatments for autoimmune diseases often rely on long-term use of steroids and immunosuppressant drugs. While these can help manage symptoms, they also increase the risk of infections, cancer, and other complications. Many patients endure years of fatigue, pain, and disability due to the lack of effective alternatives.
In recent years, scientists have explored the use of CAR-T therapy—a cutting-edge treatment originally developed for cancer—for autoimmune diseases like lupus. This therapy modifies T cells to target and destroy specific cells. However, it comes with significant side effects, including cytokine release syndrome and neurological complications. These risks are more acceptable in cancer patients, who are often older, but less so for those with chronic autoimmune conditions who are typically younger.
The Promise of CAR NK Therapy
A newer approach, known as CAR NK (Chimeric Antigen Receptor Natural Killer cells), is showing promise as a safer alternative. CAR NK cells are genetically engineered in the lab to target the cells that produce faulty antibodies. Once introduced, the immune system regenerates with healthy cells.
Compared to CAR-T therapy, CAR NK cells use a different type of white blood cell, the NK cell, to deliver the same killing effect with fewer toxicities. Additionally, CAR NK cells can be manufactured in bulk from donor umbilical cord blood or stem cells, making them more cost-effective and easier to store.
This treatment is already being tested on patients with lupus, a condition affecting around 70,000 people in the UK. After receiving an infusion of CAR NK cell therapy, 27 patients showed signs of improvement, with 70% entering full remission. No serious side effects were reported.
Another study published in Cell in June involved a patient with systemic sclerosis, a rare autoimmune disease that attacks blood vessels and connective tissue. Following treatment, the patient’s skin and blood vessels began returning to normal.
One key advantage of using natural killer cells is that they do not usually trigger rejection, eliminating the need for a tissue match. This makes the treatment more accessible and less complicated.
Future Prospects and Challenges
Professor Zhao Dongbao, a senior immunotherapy researcher at Shanghai's Naval Medical University, believes CAR NK therapy could eventually treat over ten million patients worldwide, including more than one million in the US and the UK. Plans are underway for formal clinical trials for lupus, with potential expansion to other autoimmune diseases in the future.
While the approach shows great promise, Professor Lucy Walker cautions that it is still in its early stages and has been tested on a very small number of people. She emphasizes that further research is needed to confirm its effectiveness and safety.
Luke Evnin, chair of the US-based Scleroderma Research Foundation, remains optimistic. He believes that a single course of treatment could provide lasting benefits, allowing patients to stop other medications and prevent disease progression. For many, this could be a game-changer in the fight against autoimmune diseases.